Neuro-ophthalmologic sequelae are common in MS and may arise from the disease itself or from treatment of the disease. Both afferent and efferent functions may be affected. Despite much progress ...

Researchers evaluated the frequency of severe and nonsevere relapses among patients with giant cell arteritis and assessed the characteristics associated with severe relapse.

During the PGY-4 year, residents spend one month in neuro-ophthalmology. In addition to participating in clinic, residents also have the opportunity to see various ophthalmologic surgical procedures.

Investigators recruited children with CVI and normal controls who were between the ages of 12 months and 12 years. The children with CVI underwent a complete pediatric neuro-ophthalmologic examination ...

Study: Medications for attention deficit hyperactivity disorder associated with increased risk of developing glaucoma. Image Credit: Creativan/Shutterstock.com ADHD is a neurodevelopmental disorder ...

Annual ophthalmologic exams, baseline examinations of ultrasound pachymetry, and semiannual exams of intraocular pressure were conducted on all participants. Patients were considered to have glaucoma ...

UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.

as well as various retinal pathologies (Box 1 contains definitions of ophthalmologic terms). In this paper, we will review current knowledge of the epidemiology, clinical presentation, course ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its ...

OPL-0401 has also shown evidence of pharmacological activity in a non-ophthalmologic human vascular disease ...

It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089 ...

Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.